Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Hou

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Pharmacoepidemiology and Drug Safety|May 26, 2020
Conducting prospective sequential surveillance in real-world dynamic distributed databasesJudith C Maro, Efe Eworuke, Laura Hou, et al.
Inflammatory Bowel Diseases|August 23, 2023
Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel DiseaseMillie D Long, Lauren Parlett, James D Lewis, et al.
Environmental Health Perspectives|March 31, 2018
Erratum: "A Case-Control Study of Maternal Polybrominated Diphenyl Ether (PBDE) Exposure and Cryptorchidism in Canadian Populations"Cynthia G Goodyer, Shirley Poon, Katarina Aleksa, et al.
Environmental Health Perspectives|May 31, 2017
A Case-Control Study of Maternal Polybrominated Diphenyl Ether (PBDE) Exposure and Cryptorchidism in Canadian PopulationsCynthia G Goodyer, Shirley Poon, Katarina Aleksa, et al.
Pharmacoepidemiology and Drug Safety|December 16, 2021
Validation of diagnosis codes to identify hospitalized COVID-19 patients in health care claims dataSheryl A Kluberg, Laura Hou, Sarah K Dutcher, et al.
Thrombosis Journal|October 9, 2015
Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective studyMurray M Bern, Diane Hazel, Elizabeth Deeran, et al.
Pharmacoepidemiology and Drug Safety|September 18, 2024
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and DenmarkEfe Eworuke, Mayura U Shinde, Laura Hou, et al.
Pharmaceutical Medicine|January 15, 2020
Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin UsersRyan M Carnahan, Joshua J Gagne, Christian Hampp, et al.
BMJ Open|April 17, 2023
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort studyEfe Eworuke, Mayura Shinde, Laura Hou, et al.
Inflammatory Bowel Diseases|June 26, 2023
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative ColitisSruthi Adimadhyam, James D Lewis, Andrew L Simon, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Pharmacoepidemiology and Drug Safety|May 26, 2020
Conducting prospective sequential surveillance in real-world dynamic distributed databasesJudith C Maro, Efe Eworuke, Laura Hou, et al.
Inflammatory Bowel Diseases|August 23, 2023
Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel DiseaseMillie D Long, Lauren Parlett, James D Lewis, et al.
Environmental Health Perspectives|March 31, 2018
Erratum: "A Case-Control Study of Maternal Polybrominated Diphenyl Ether (PBDE) Exposure and Cryptorchidism in Canadian Populations"Cynthia G Goodyer, Shirley Poon, Katarina Aleksa, et al.
Environmental Health Perspectives|May 31, 2017
A Case-Control Study of Maternal Polybrominated Diphenyl Ether (PBDE) Exposure and Cryptorchidism in Canadian PopulationsCynthia G Goodyer, Shirley Poon, Katarina Aleksa, et al.
Pharmacoepidemiology and Drug Safety|December 16, 2021
Validation of diagnosis codes to identify hospitalized COVID-19 patients in health care claims dataSheryl A Kluberg, Laura Hou, Sarah K Dutcher, et al.
Thrombosis Journal|October 9, 2015
Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective studyMurray M Bern, Diane Hazel, Elizabeth Deeran, et al.
Pharmacoepidemiology and Drug Safety|September 18, 2024
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and DenmarkEfe Eworuke, Mayura U Shinde, Laura Hou, et al.
Pharmaceutical Medicine|January 15, 2020
Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin UsersRyan M Carnahan, Joshua J Gagne, Christian Hampp, et al.
BMJ Open|April 17, 2023
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort studyEfe Eworuke, Mayura Shinde, Laura Hou, et al.
Inflammatory Bowel Diseases|June 26, 2023
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative ColitisSruthi Adimadhyam, James D Lewis, Andrew L Simon, et al.
Pageof 3